"That they can exclude a
drug just because it's made a minimal change to an older drug, even one that's
still on the market, is huge. And it is going to force the pharmaceutical
companies to work more within the formulary managed care communication."
— Michael Strazzella, practice group
leader for federal government relations and administrative head of the
Washington, D.C., law office of Buchanan, Ingersoll & Rooney, talked with
AIS's RADAR on Medicare Advantage
about CMS's proposed rules on protected class drugs.
No comments:
Post a Comment